MedTrace Logo

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

NCT03195400 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-02-23

No results posted yet for this study

Summary

Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incretin system and hepatic insulin resistance in obese adolescents. The long-term goal of this study is to generate information on both the genetics as well as the pathophysiology of Type 2 Diabetes in Youth, which ultimately might guide the investigators towards better preventive and treatment avenues.

Conditions

  • IGT - Impaired Glucose Tolerance
  • T2D

Interventions

DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.

DIAGNOSTIC_TEST

Hyperglycemic Clamp

Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.

DIAGNOSTIC_TEST

Isoglycemic Intravenous Glucose Test

Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.

DIAGNOSTIC_TEST

Hyperinsulinemic Euglycemic Clamp and 2H20

Test is used to assess insulin effects on hepatic glucose production.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Sonia Caprio, MD · Yale University

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2021-08-31
Completion
2022-08-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03195400 on ClinicalTrials.gov